Perseo pharma AG is focused on developing innovative oral enzyme therapies aimed at treating digestive diseases, particularly those resulting from enzyme deficiencies. The company is leveraging a proprietary nanotechnology platform that enhances the stability and efficacy of enzymes in the gastrointestinal tract. This technology involves encapsulating enzymes in a nano-shield, which protects them from degradation in the harsh environment of the digestive system and facilitates their targeted delivery to the mucus of the small intestine. By improving the digestion efficiency and reducing the pill burden for patients, Perseo pharma aims to provide more effective treatment options for conditions such as Exocrine Pancreatic Insufficiency (EPI) and other digestive disorders.

In collaboration with Nestlé Health Science, Perseo pharma is advancing multiple therapeutic programs, including the development of PER301, a pancreatic enzyme replacement therapy. This partnership aims to address the limitations of current oral enzyme therapies, which often require patients to take numerous pills daily, leading to inefficiencies in nutrient absorption. The focus on patient-centered solutions underscores Perseo pharma's commitment to transforming the treatment landscape for individuals suffering from digestive enzyme deficiencies, with the potential to significantly improve their quality of life.

Switzerland

Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma's therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease.

Perseo pharma AG

Company Details